FREE RAC Regulatory Strategic Planning Questions and Answers

Question 1

A pharmaceutical company is developing a novel drug-eluting stent, a product combining a drug and a device.
To formulate an effective regulatory strategy in the United States, what is the MOST critical initial step?

Accepted Answer

Submitting a Request for Designation (RFD) to the Office of Combination Products (OCP) to determine the product's Primary Mode of Action (PMOA).

Answer

Beginning clinical trials immediately to gather efficacy data for both the drug and device components.

Answer

Developing separate marketing applications for the drug and device components to streamline the review process.

Answer

Engaging a contract manufacturing organization that is compliant with both 21 CFR 211 and 21 CFR 820.

Question 2

A company is creating a global regulatory strategy for a new Class II medical device. Which of the following activities is essential to perform during the earliest stages of strategic planning?

Accepted Answer

Identifying and defining the device's intended use and target patient population.

Answer

Conducting a comprehensive gap analysis of the technical documentation against the requirements of all target markets.

Answer

Finalizing the marketing and promotional materials for all target countries.

Answer

Translating the full user manual into the languages of all potential markets.

Question 3

Which of the following BEST describes the role of a Target Product Profile (TPP) in regulatory strategic planning?

Accepted Answer

It is a dynamic, strategic tool that outlines the desired product characteristics to guide development and facilitate alignment with regulatory authorities.

Answer

It is a legally binding contract submitted to regulatory authorities outlining the final, unchangeable product specifications.

Answer

It is primarily a marketing document used to secure funding from investors and has minimal impact on regulatory interactions.

Answer

It is a static document created at the end of the development process to summarize the product's final characteristics for labeling.

Question 4

A biotech company is developing a new biologic therapy for a serious, life-threatening disease with no current effective treatment. To potentially shorten the time to market, the company's regulatory strategy should prioritize:

Accepted Answer

Evaluating the criteria for one of the FDA's expedited programs, such as Breakthrough Therapy or Fast Track designation.

Answer

Applying for a standard Biologics License Application (BLA) pathway to ensure a thorough and complete review.

Answer

Avoiding all interaction with the FDA until the final BLA is ready for submission to maintain data confidentiality.

Answer

Focusing exclusively on manufacturing process optimization before initiating any clinical studies.

Question 5

When developing a regulatory strategy, what is the primary purpose of pre-submission meetings and other formal interactions with health authorities?

Accepted Answer

To gain clarity on regulatory expectations, obtain guidance on the development plan, and de-risk the submission process.

Answer

To obtain a binding guarantee of product approval before submitting the formal application.

Answer

To negotiate lower user fees for the marketing application review.

Answer

To receive informal, non-binding feedback from competitors about the development plan.

Question 6

A key distinction between a regulatory STRATEGY and a regulatory PLAN is that a strategy:

Accepted Answer

considers the entire product lifecycle and aligns regulatory activities with broader business objectives.

Answer

focuses only on the post-market surveillance activities required for the product.

Answer

is a simple checklist of submission documents and their due dates.

Answer

is only created after a product has been rejected by a regulatory agency.

A pharmaceutical company is developing a novel drug-eluting stent, a product combining a drug and a device.To formulate an effective regulatory strategy in the United States, what is the MOST critical initial step?

A pharmaceutical company is developing a novel drug-eluting stent, a product combining a drug and a device.
To formulate an effective regulatory strategy in the United States, what is the MOST critical initial step?